If you’re researching GLP-1 medications for weight loss, you’ve likely come across two names that dominate the conversation: Retatrutide and Ozempic. While Ozempic (semaglutide) has been a household name since its FDA approval, Retatrutide represents the next generation of weight loss medications—and the results are turning heads in the medical community.
Understanding How These GLP-1 Medications Work
What is Ozempic (Semaglutide)?
Ozempic is a GLP-1 receptor agonist originally developed for Type 2 diabetes management. It works by mimicking the glucagon-like peptide-1 hormone, which slows gastric emptying, reduces appetite, and helps regulate blood sugar levels.
What is Retatrutide?
Retatrutide is a triple-agonist medication currently in late-stage clinical trials. Unlike Ozempic’s single-target approach, Retatrutide activates three different receptors: GLP-1, GIP, and Glucagon receptor—which may explain its potentially superior weight loss results.
Comparing Weight Loss Results
Ozempic Weight Loss Data
Patients on Ozempic typically lose 10-15% of body weight over 12-18 months.
Retatrutide Weight Loss Data
Phase 2 trial results show up to 24% body weight loss at the highest dose—results that rival bariatric surgery without going under the knife.
FAQ
Is Retatrutide FDA approved?
As of February 2026, Retatrutide is still in Phase 3 clinical trials and has not yet received FDA approval.
Can I switch from Ozempic to Retatrutide?
Once Retatrutide becomes available, switching may be possible under medical supervision. Consult your healthcare provider.
Which GLP-1 medication has fewer side effects?
Both medications share similar gastrointestinal side effects. Ozempic has more long-term safety data available.